文献速递血管炎

18F-氟脱氧葡萄糖正电子发射断层扫描监测托珠单抗对巨细胞动脉炎血管炎症的疗效

Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

PETVAS从基线24.0(IQR 22.3-27.0)显著降至最近随访18.5(IQR 15.3-23.8,P<0.01),两年治疗期内线性趋势显著(P<0.01),停药后6例中5例PET活性恶化,2例临床复发。

要点

  • 托珠单抗治疗与GCA患者PETVAS显著降低相关,两年内持续改善。
  • 停药后多数患者FDG-PET血管活性恶化,部分出现临床复发。
  • FDG-PET可用于监测GCA血管炎症对托珠单抗的治疗反应。

核心结论

  • 托珠单抗治疗GCA与临床改善及系列FDG-PET所测血管炎症减轻相关。

研究设计与样本

  • 前瞻性观察队列中选取接受托珠单抗治疗的GCA患者,基线和每6个月行FDG-PET,影像盲法判读,用PETVAS量化动脉FDG摄取。

主要发现

  • PETVAS从基线24.0(IQR 22.3-27.0)降至最近随访18.5(IQR 15.3-23.8),P<0.01。
  • 两年治疗期内PETVAS线性下降趋势显著(P<0.01),第一年和第二年改善程度相似。
  • 停药后重复FDG-PET显示6例中5例PET活性恶化,其中2例随后临床复发。

临床怎么用

  • 对接受托珠单抗治疗的GCA患者,可考虑系列FDG-PET监测血管炎症反应。
  • 停药后需警惕PET血管活性恶化及临床复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the time-dependent effects of tocilizumab on vascular inflammation as measured by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in GCA. METHODS: Patients with GCA treated with tocilizumab were selected from a prospective, observational cohort. Patients underwent FDG-PET at the baseline visit prior to initiation of tocilizumab and at subsequent follow-up visits performed at 6-month intervals. All imaging findings were interpreted blinded to clinical data. The PET vascular activity score (PETVAS) was used to quantify arterial FDG uptake. Wilcoxon signed rank test was used to compare change in PETVAS between visits. Linear regression was used to determine change in PETVAS over multiple timepoints. RESULTS: Twenty-five patients with GCA were included. All patients had physician-determined active vasculitis at the baseline visit by clinical assessment and FDG-PET interpretation. PETVAS was significantly reduced in association with tocilizumab treatment from the baseline to the most recent follow-up visit [24.0 (IQR 22.3-27.0) vs 18.5 (IQR 15.3-23.8); P <0.01]. A significant reduction in PETVAS was observed over a two-year treatment period (P <0.01 for linear trend), with a similar degree of improvement in both the first and second years of treatment. Repeat FDG-PET scans after tocilizumab discontinuation showed worsening PET activity in five out of six patients, with two patients subsequently experiencing clinical relapse. CONCLUSION: Treatment of patients with GCA with tocilizumab was associated with both clinical improvement and reduction of vascular inflammation as measured by serial FDG-PET. Future clinical trials in GCA should study direct treatment effect on vascular inflammation as an outcome measure.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Quinn KA, Dashora H, Novakovich E, et al. Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis. Rheumatology (Oxford). 2021. PMID: 33369678. doi:10.1093/rheumatology/keaa894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。